Objectives: To describe regional differences and trends in resistance testing among individuals experiencing virological failure and the prevalence of detected resistance among those individuals who had a genotypic resistance test done following virological failure.
Introduction
Combination antiretroviral therapy (cART) has brought considerable clinical and public health benefits, by suppressing HIV-1 replication and consequently allowing CD4 þ cell counts to increase [1] [2] [3] . However, in cases of incomplete viral suppression, resistance to antiviral drugs may develop [4] . Such acquired drug resistance limits the number of available treatment options, compromises the benefits of cART by impairing the response to therapy and could also contribute to the transmission of drug-resistant HIV strains [5] [6] [7] . Given these clinical consequences, monitoring trends in resistance prevalence is important.
Prevalence estimates from observational studies tend to rely on resistance tests done as part of routine clinical care in order to access genotypic data. Whether or not a resistance test is performed following virological failure is a matter of clinical judgment and cost, but there are several clinical guidelines available to guide decisions. Current European as well as US guidelines recommend testing for drug resistance at both initiation of therapy and following virological failure [8, 9] ; however, this has not always been the case. Since resistance testing first became widely available in the late 1990s, clinical guidelines have changed. This is in part to reflect the results from trials showing that knowledge of a patient's resistance profile results in treatment benefits [10] [11] [12] [13] , and partly due to the implementation of technologies that allow genotyping at lower viral loads [14, 15] . This, coupled with the fact that resistance testing technologies have become more widely available and affordable, has resulted in a changing proportion of ART-experienced individuals receiving resistance tests in clinics over time [9] . Such changes complicate estimates of resistance prevalence and in particular the comparison of prevalence estimates between different studies, as the denominator varies with time and between different studies and countries. This makes trends in resistance testing important for interpreting prevalence estimates, particularly when these are derived from observational studies.
For this reason, the aims of the current analysis were first, to describe regional differences and trends in resistance testing among individuals experiencing virological failure, and second, to describe regional differences and trends in the prevalence of detected resistance among those individuals who had a genotypic resistance test.
Study population and methods
The EuroSIDA study EuroSIDA is a large, ongoing prospective cohort study of more than 18 000 individuals living with HIV. At the time of analysis, the study collected data from 111 hospitals in 34 different countries across Europe, as well as Israel and Argentina [1] . For this analysis, these countries have been grouped into five different regions (Southern Europe, Central Western Europe, Northern Europe, Central Eastern Europe and Eastern Europe, as detailed in Supplementary Digital Content 2, http://links.lww.com/QAD/ A700) as described previously [16] . Recruitment started in 1994, and data were collected 6-monthly on standardized case report forms (CRFs). Variables collected include demographic information, CD4 þ cell counts, viral load measurements, as well as start and stop dates for all antiretroviral drugs used. All patients gave informed consent at enrolment, as described at www.cphiv.dk. An extensive programme of quality control is in place, details of which have been previously published [16, 17] .
Resistance data Virological reports of resistance tests done by clinicians as part of routine clinical care are submitted to a centralized resistance database held at the IrsiCaixa Foundation, Badalona, Spain. The methods used to test for resistance differs depending on the centre, and our database contains very limited information on this. Clinicians can also indicate whether or not an individual's virus has been genotyped since the last clinic visit in the main CRF. These data give no genotypic information, and could therefore not be used to address the second aim of this particular study.
Resistance mutations were defined using the International Antiviral Society (IAS)-USA (2013) guidelines [18] . Throughout the article, 'any resistance mutation' will refer to at least one detected IAS-USA resistance mutation to nucleoside reverse-transcriptase inhibitor (NRTI), nonnucleoside reverse-transcriptase inhibitor (NNRTI) or protease inhibitor (PI) drug classes, excluding minor PI mutations. As the analysis focused on detected drug resistance at a single time point, resistance mutations were not carried forward in a cumulative manner.
Inclusion criteria
All individuals aged above 16 years with evidence of virological failure (having a viral load measurement >500 copies/ml while on ART after at least 6 months of ART exposure [8] ) after 1 January 1997 were considered eligible for a resistance test and were included in this analysis. We consciously used a broad definition of virological failure for our primary analysis in order to maximize the number of individuals that we could include. For any given year, a person was included if they experienced virological failure in that year, and considered as having a resistance test associated with the virological failure in that year if they had a resistance test no more than 1 month before or 12 months after the date of virological failure. If the same resistance test could be linked to more than one virological failure date in different calendar-years, it was attributed to the virological failure date occurring closest to the test. Individuals contributed one measurement for each year in which they experienced virological failure. This means that individuals could contribute data for more than 1 calendar-year, and were not excluded after they had their first virological failure or resistance test. The first included date of virological failure for each individual was considered as the baseline date for that person, and the characteristics of the study population at baseline were summarized.
Statistical methods
The proportion of individuals with a resistance test following virological failure (first aim of the study) and detected resistance after having a test (second aim of the study) was plotted against calendar-year with 95% confidence intervals (CIs). Logistic regression models with generalized estimating equations (GEEs) [19, 20] were used to identify predictors and to test for changes in the prevalence of resistance testing and detected resistance. The rationale for which covariates to include in the multivariable models was based on clinical knowledge and previous publications [21, 22] , and included factors hypothesized to be associated with our exposures of interest and the relevant outcome. Adjustments are detailed in the relevant tables ( Table 2 , Supplementary Digital Content 3, http://links.lww.com/QAD/A700).
We also studied factors associated with virological failure in order to add to the context of the current analysis. This model was adjusted for age, sex, ethnicity, mode of HIV transmission, region, previous history of mono/dual therapy use, number of available previous resistance tests, CD4 þ cell count, previous history of virological failure and calendar-year.
P values of less than 0.05 were taken to indicate statistical significance. All analyses were conducted using SAS 9.3 (Statistical Analysis Software, Cary, North Carolina, USA).
Sensitivity analyses
Several sensitivity analyses (Supplementary Digital Content 5, http://links.lww.com/QAD/A700) were done using varying definitions of virological failure. Table 1 ; the majority of the individuals included were men (75%) and white (86%), and 40% had acquired their HIV infection through sex with another man.
Results

Characteristics
Resistance testing
Trends in proportion of individuals with a resistance test over time Of the 8469 individuals experiencing virological failure, a total of 2676 (31.6%) were tested for resistance in at least one of the years in which they had evidence of virological failure. Among those who had a test, the median time between the date of virological failure and a resistance test was 0.7 months [inter-quartile range (IQR) 0-4 months; range 1-12 months]. Of those with at least one resistance test, 60.7% had one test, 23.5% had two tests, 8.5% had three tests and 7.3% had four or more resistance tests. The mean number of tests done per person was lower in Eastern Europe compared to other regions (P < 0.001; mean ¼ 0.6 compared to mean ¼ 1.2 in Northern Europe). Multivariable models of factors associated with having a resistance test The association between calendar-year of virological failure and the probability of having a resistance test was confirmed in multivariable analysis (global P < 0.001, Supplementary Digital Content 4, http://links.lww. com/QAD/A700), and adjustment for potential confounders had only a limited influence on the calendaryear effect estimates.
Compared to Southern Europe, individuals were more likely to be tested for resistance at or after virological failure in Northern Europe (aOR 2.15, 95% CI 1.96-2.36, P < 0.001) and Central Western Europe (aOR 1.66, 95% CI 1.51-1.82, P < 0.001). In contrast, individuals in Eastern Europe were less likely to be tested (aOR 0.72, 95% CI 0.55-0.94, P ¼ 0.02) compared to individuals in Southern Europe. As expected, individuals with RNA levels of 1000-10 000 copies/ml at virological failure were more likely to have a resistance test compared to individuals with lower viral loads (aOR 2.10, 95% CI 1.86-2.37, P <.001 compared to 500-999 copies/ml, Supplementary Digital Content 2, http://links.lww.com/QAD/A700). Due to a small number of individuals being tested for resistance per region and per calendar-year, we did not perform a formal interaction test as this would be underpowered and restricted by empty cells in the regression model. However, plotting the time-trends by region showed that both the rise and decline in resistance testing following virological failure was somewhat more marked in Northern, Central Western and Southern Europe compared to Central Eastern and Eastern Europe (Fig. 1b) , although the numbers were limited.
Detected drug resistance
Trends in proportion of individuals with detected drug resistance over time In total, 2431 (77.9%) of the 3119 resistance tests with genotypic data detected drug resistance. The prevalence of mutations with more than 10% prevalence is shown in Fig. 2 . Overall, NRTI resistance was most commonly detected in 70.3% of the tests, followed by NNRTI (51.6%) and PI (46.1%) resistance. The most commonly detected individual mutations were M184V (46.3%, NRTI), K103NS (23.4%, NNRTI) and L90M (26.8%, PI). Changes in the proportion of individuals with detected drug resistance each year can be seen in Fig. 3 , both overall and after stratification by drug class. Univariable models indicated that calendar-year was associated with the detection of drug resistance (global P < 0.001). This trend was not linear, and the prevalence appeared to increase until 2003-2004 followed by somewhat of a decrease. In 1997, just less than twothirds of the population had detected resistance, and this was somewhat higher (84%) in 2003. In 2012, an estimated 79% of the individuals had detected drug resistance. Looking at univariable specific contrasts, we found strong evidence (all P < 0. (Table 2 ).
Multivariable models of factors associated with detected drug resistance The odds of detecting drug resistance varied by calendar time also after adjustment for confounding (global P < 0.001), with the odds of detecting any resistance being lower before and after [2003] [2004] (Table 2) . Individuals were less likely to have resistance detected in Northern (aOR 0.29, 95% CI 0.21-0.39, P <.001) and Central Eastern Europe (aOR 0.47, 95% CI 0.29-0.76, P ¼ 0.002) compared to Southern Europe. A number of other factors were independently associated with the risk of resistance detection. Individuals with a history of mono/dual therapy were more likely to have detected drug resistance (aOR 1.54 vs. those who started cART from ART naive, 95% CI 1.14-2.08, P ¼ 0.007), as were individuals who had experienced virological failure previously (aOR 1.85 vs. those who experienced virological failure for the first time, 95% CI 1.40-2.45, P < 0.001). Individuals with RNA levels between 1000 and 10 000 copies/ml were more likely to have detected resistance (aOR 1.63, compared to individuals with RNA levels less than 1000 95% CI 1.19-2.23, P ¼ 0.002), but individuals with very high RNA levels (>50 000 copies/ml) were not significantly more likely to have detected resistance (aOR 1.20, 95% CI 0.84-1.72) compared to individuals with RNA levels less than 1000. Findings were broadly consistent when conducting the analysis for each drug class separately (data not shown).
Sensitivity analyses
The estimates of the prevalence of virological failure and resistance in a number of sensitivity analyses are shown in Supplementary Digital Content 5 (http://links.lww.-com/QAD/A700). Briefly, the proportion of individuals with a resistance test was higher when using stricter criteria to define virological failure, including only considering virological failures that were followed by a switch in regimen, but remained below 50%. The proportion of resistance tests with detected drug resistance remained reasonably stable despite using stricter definitions of virological failure. Multivariable results from these sensitivity analyses were in broad agreement with the results described above (data not shown).
Discussion
In this analysis of a large cohort of HIV-positive individuals with virological failure from across Europe, around one-third of the individuals received a resistance test within 12 months of virological failure. This proportion decreased after 2004. The relatively low proportion of individuals in our study receiving a resistance test at or after virological failure extend and confirm previous EuroSIDA findings [21] practice and current guidelines which recommend to always test for resistance after virological failure.
Several clinical trials have shown a direct clinical benefit of resistance testing [10] [11] [12] [13] , and it is important to encourage the use of genotyping by clinicians. However, clinical decisions are complicated by numerous factors and it is not uncommon that guidelines are not followed exactly in real life. The fact that the proportion tested for resistance is higher when considering virological failure followed by a switch in a sensitivity analysis is reassuring, as it indicates that clinicians may test selectively those individuals they are considering switching to a different drug class. Adjustment for a range of clinical variables did not affect the declining trend observed after 2004; however, we cannot rule out that this result might have been different if we could control for other unmeasured factors that could influence clinicians' decisions to order a resistance, such as an increased availability of different drugs. In addition, the marked reduction in the proportion of individuals experiencing virological failure over time documented here indicates that virological failure is becoming less common. It could be that when seen in a clinical setting, the reason for the virological failure may be put down to poor adherence, a chaotic lifestyle or personal issues rather than drug resistance. This is in agreement with the higher proportion of adherent individuals having a resistance test observed in the sensitivity analyses. However, it should be noted that the adherence data available is of limited scope, and findings should therefore be interpreted with caution.
Other studies of trends in resistance testing have found conflicting results. A recent study of drug resistance HIV resistance testing and prevalence Schultze et al. 1385 prevalence in Sweden provided data on the number of tests done over time, and showed that these remained relatively stable [23] . This also appears to be the case in the United States, at least from 2003 onwards [24] . Nonetheless, our results are in broad agreement with a study conducted in British Columbia, Canada, from 2011, which found both under-utilization of resistance testing as well as a lower probability of testing after 2004 [25] . An analysis of data from the UK Collaborative HIV Cohort Study cohort has shown that 46% of individuals had a resistance test after viral rebound prior to a change in therapy, similar to the estimate of 47% we found when defining failure according to whether or not a high viral load was followed by a switch in the regimen [26] .
Despite a declining trend in resistance testing, a relatively high proportion -almost 80% -of tests detected any drug resistance. This estimate is comparable to those obtained from other European cohorts [27] , but somewhat higher than data obtained from the United Kingdom [28] , potentially due to differences in the populations studied. The fact that a relatively high proportion of resistance tests did detect drug resistance could indicate that clinicians may be taking a selective approach to resistance testing, whereby those individuals judged most likely to have resistance are also the ones offered a test.
The proportion of tests detecting any resistance peaked in 2003-2004, and there was some evidence to suggest that this proportion had declined in the more recent calendaryears. A decline in the prevalence of resistance in recent years among individuals experiencing virological failure has been found in a number of European cohorts [22, 23, 28, 29] and also in the USA [30] . Such a decrease could be explained by improvements in the potency of drugs used, minimized side effects and an increase in therapeutic options that have all lowered the risk of developing drug resistance [22, 29] . Simplified drug regimens that are easier to take, combined with efforts to educate patients, and the development and use of drugs with a high genetic barrier may also play an important role. Taken together with the reduced proportion of individuals experiencing virological failure in more recent calendar-years, the current analysis documents a marked reduction in the number of individuals experiencing virological failure with acquired drug resistance.
Regional differences in the probability of both receiving a resistance test and detecting drug resistance were observed. Clinicians in Northern Europe were the most likely to test for resistance following virological failure, but also least likely to detect any drug resistance once the test was prescribed. In contrast, clinicians in Eastern Europe were comparatively less likely to test for resistance following virological failure compared to Central Western and Northern Europe, but also more likely to detect resistance when doing a test compared to Central Eastern and Northern Europe. As it is unlikely that the biological probability of developing drug resistance in a situation of virological failure differs according to region, it is possible that the lower testing rates in Eastern Europe are causing individuals to be maintained on failing therapies for longer, thus leading to the development of resistance. Clinicians in Eastern Europe may also be more selective about who they test for resistance, as indicated in a recent EuroSIDA survey [31] .
Our findings should be interpreted with caution as the analysis was subject to several limitations. First of all, the definition of virological failure referred to by guidelines for resistance testing has changed over time. We attempted to address this possible bias in sensitivity analyses, and although the proportion receiving a test increased with more stringent definitions of virological failure, it still remained relatively low. Furthermore, we cannot rule out under-reporting of the numbers of tests ordered and performed from the clinical sites, although rigorous efforts are made to minimize such underreporting by quality control visits. Resistance tests done in more recent years might also be subject to reporting delay, which similarly may have led to an underestimation of the number of tests done after a certain calendar period. We furthermore cannot exclude that some instances of virological failure have been misclassified. It is possible that some of the virological failures, particularly early on during follow-up, may be due to treatment interruptions. Finally, EuroSIDA clinics may not be representative of all HIV clinics in Europe, as some countries are represented by relatively few centres. It should also be noted that the prevalence of detected drug resistance in this study differs from the true population level prevalence of drug resistance, which requires genotypic data from all individuals on ART or some estimation of the prevalence of resistance in those who were not tested. We have taken this latter approach in one of our previous publications, which provided an estimate of the overall population level prevalence of resistance in 1 year (i.e. 2008) [32] .
To conclude, our findings indicate that the clinical approach to resistance testing may diverge from that laid out in guidelines, and we observed calendar-year and regional differences both in resistance testing and the probability of detecting resistance. Public health policy aimed at minimizing the emergence of drug resistance might benefit from targeting specific regions of Europe, and efforts to minimize inter-regional differences in the availability and utilization of resistance testing in the European region may be warranted.
